It appears that your browser has cookies disabled.
The website requires your browser to enable cookies in order to login.
Please enable cookies and reload this page.
Advancing Cancer Diagnostics, Improving Lives
Select Your Country/Region
Your location doesnt match the address (URL), do you want to change it?
Each country/region may have its own set of regulatory requirements and medical practices. The information found on each country version of our website is specific to and applicable for only that country/region. This includes (but is not limited to) all product details/availability, documentation, pricing, and promotions.
Hodgkin’s lymphoma: in situ hybridization for Epstein-Barr virus (EBV) encoded mRNA using EBER Probe, Anti-Fluorescein Antibody and BOND Polymer Refine Detection.
Hodgkin’s lymphoma: in situ hybridization for Epstein-Barr virus (EBV) encoded mRNA using EBER Probe, Anti-Fluorescein Antibody and BOND Polymer Refine Detection.
BOND EBER Probe
BOND ISH probes are provided in a ready-to-use format and their use has been validated together with Leica ancillaries and BOND Polymer Refine detection for quality you can depend on. Turnaround time is rapid – around 4 hours 20 minutes using the standard BOND protocol, enabling the rapid turnaround of results vs. typical overnight protocols or outsourced testing, for improved patient care.
Background Epstein-Barr Virus (EBV) is a member of the Gamma Herpes Virus family. EBV can establish both lytic infection as well as latent infection.
Epstein Barr Virus encoded RNA is abundantly expressed in latent EBV infection and ISH is considered a sensitive method for the detection of latent EBV infection.
Latent EBV infection is associated with several conditions including: Hodgkin's Lymphoma, B cell Non Hodgkin's Lymphoma, nasopharyngeal carcinoma, lymphoproliferative disorders and lymphoma in the immunosuppressed, including transplant and AIDS patients, gastric cancer and some T cell lymphomas.
